Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly D Leuthner

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Clinical Microbiology|August 9, 2013
Antimicrobial stewardship programsKimberly D Leuthner, Gary V Doern
Journal of Pharmacy Practice|August 16, 2013
Antimicrobial stewardship and Clostridium difficile-associated diarrheaFrank J Piacenti, Kimberly D Leuthner
Antimicrobial Agents and Chemotherapy|January 27, 2006
Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniaeKimberly D Leuthner, Chrissy M Cheung, Michael J Rybak
The Journal of Antimicrobial Chemotherapy|June 22, 2006
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureusKimberly D Leuthner, Chrissy M Cheung, Michael J Rybak
Expert Review of Anti-Infective Therapy|January 13, 2015
Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infectionKimberly D Leuthner, Angela Yuen, Yu Mao, et al.
Antimicrobial Agents and Chemotherapy|June 30, 2010
In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolatesKimberly D Leuthner, Celine Vidaillac, Chrissy M Cheung, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2006
Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic modelKerry L LaPlante, Michael J Rybak, Kimberly D Leuthner, et al.
Therapeutics and Clinical Risk Management|June 30, 2016
Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)Kimberly D Leuthner, Kristin A Buechler, David Kogan, et al.
Germs|April 29, 2026
Variety of <i>Clostridioides difficile</i> Ribotypes in CDI Patients in Las Vegas, NVAmber Consul, Mohamad Mubder, Samrawit Misiker, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Clinical Microbiology|August 9, 2013
Antimicrobial stewardship programsKimberly D Leuthner, Gary V Doern
Journal of Pharmacy Practice|August 16, 2013
Antimicrobial stewardship and Clostridium difficile-associated diarrheaFrank J Piacenti, Kimberly D Leuthner
Antimicrobial Agents and Chemotherapy|January 27, 2006
Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniaeKimberly D Leuthner, Chrissy M Cheung, Michael J Rybak
The Journal of Antimicrobial Chemotherapy|June 22, 2006
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureusKimberly D Leuthner, Chrissy M Cheung, Michael J Rybak
Expert Review of Anti-Infective Therapy|January 13, 2015
Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infectionKimberly D Leuthner, Angela Yuen, Yu Mao, et al.
Antimicrobial Agents and Chemotherapy|June 30, 2010
In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolatesKimberly D Leuthner, Celine Vidaillac, Chrissy M Cheung, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2006
Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic modelKerry L LaPlante, Michael J Rybak, Kimberly D Leuthner, et al.
Therapeutics and Clinical Risk Management|June 30, 2016
Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)Kimberly D Leuthner, Kristin A Buechler, David Kogan, et al.
Germs|April 29, 2026
Variety of <i>Clostridioides difficile</i> Ribotypes in CDI Patients in Las Vegas, NVAmber Consul, Mohamad Mubder, Samrawit Misiker, et al.
Pageof 1